Browsing by Author "Jackman, David M"
Now showing items 1-6 of 6
-
Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer
Li, Richard Jay; Hermann, Gretchen; Baldini, Elizabeth Healey; Chen, Aileen Betty; Jackman, David M; Kozono, David Eiichi; Nguyen, Paul Linh; Nohria, Anju; Powell, Graham; Mak, Raymond Heungwing (Elsevier BV, 2016)Objectives: Patients with non-small cell lung cancer (NSCLC) are known to be at high risk for venous thromboembolism (VTE), but previous studies have not specifically analyzed locally advanced disease. We performed a ... -
Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival
Gray, Phillip; Mak, Raymond Heungwing; Yeap, Beow Yong; Cryer, Sarah K.; Pinnell, Nancy E.; Christianson, Laura W.; Sher, David J.; Arvold, Nils; Baldini, Elizabeth Healey; Chen, Aileen Betty; Kozono, David Eiichi; Swanson, Scott James; Jackman, David M; Alexander, Brian Michael (Elsevier BV, 2014)Objectives: Optimal therapy for patients with non-small cell lung carcinoma (NSCLC) presenting with synchronous brain-only oligometastases (SBO) is not well defined. We sought to analyze the effect of differing therapeutic ... -
EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
Sholl, Lynette Marie; Xiao, Yun; Joshi, Victoria; Yeap, Beow Yong; Cioffredi, Leigh-Anne; Jackman, David M; Lee, Charles; Janne, Pasi Antero; Lindeman, Neal I. (Oxford University Press (OUP), 2010)About 10% of patients with non–small cell lung carcinoma (NSCLC) respond to epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs). More than 75% of “responders” have activating mutations in ... -
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
Awad, Mark Magdi; Oxnard, Geoffrey Raymond; Jackman, David M; Savukoski, Daniel O.; Hall, Dimity; Shivdasani, Priyanka; Heng, Jennifer C.; Dahlberg, Suzanne Eleanor; Janne, Pasi Antero; Verma, Suman; Christensen, James; Hammerman, Peter Seth; Sholl, Lynette Marie (American Society of Clinical Oncology (ASCO), 2016)Purpose Non–small-cell lung cancers (NSCLCs) harboring mutations in MET exon 14 and its flanking introns may respond to c-Met inhibitors. We sought to describe the clinical, pathologic, and genomic characteristics of ... -
Pathologic Characteristics of NUT Midline Carcinoma Arising in the Mediastinum
Evans, Andrew G.; French, Christopher Alexander; Cameron, Michael J.; Fletcher, Christopher D M; Jackman, David M; Lathan, Christopher Scott; Sholl, Lynette Marie (Ovid Technologies (Wolters Kluwer Health), 2012)NUT midline carcinomas (NMC) comprise a group of highly aggressive tumors that have been reported primarily in the head, neck, and mediastinum of younger individuals. These tumors overexpress the nuclear protein in testis ... -
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
Nishinoa, Mizuki; Cryer, Sarah K.; Okajim, Yuka; Sholl, Lynette Marie; Hatabu, Hiroto; Rabin, Michael Seth; Jackman, David M; Johnson, Bruce Evan (E-MED LTD, 2012)Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with ...